findmyKOL

Robert Orlowski, MD

Enriched profile

Chair, Lymphoma/Myeloma (2025-present); Deputy Chair, Myeloma Translational Research, Division of Cancer Medicine; Professor, Lymphoma/Myeloma; Florence Maude Thomas Cancer Research Professor · The University of Texas MD Anderson Cancer Center

ORCIDNPI
Region🇺🇸 Houston, TX · South Central · United StatesSpecialtyHematology / OncologyFocusMultiple Myeloma+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2008–2026

Robert Orlowski is Chair, Lymphoma/Myeloma (2025-present); Deputy Chair, Myeloma Translational Research, Division of Cancer Medicine; Professor, Lymphoma/Myeloma; Florence Maude Thomas Cancer Research Professor at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 1,164 publications with 54,018 citations (h-index 102); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory. Clarivate lists Robert Orlowski as a Highly Cited Researcher (Clinical Medicine, 2021-2023).

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Robert Orlowski, MD, is Chair, Lymphoma/Myeloma (2025-present) at The University of Texas MD Anderson Cancer Center. The public record shows 1,164 publications with 54,018 citations (h-index 102), centered on Multiple Myeloma, Leukemia (AML/ALL/CML/CLL), Breast Cancer. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 20 companies, 6 NIH-funded awards (2008–2026).

  • Most recent indexed publication: 2026 · Blood advances
  • Top research focus: Multiple Myeloma
  • 10 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 20 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Multiple Myeloma7 trialsLeukemia (AML/ALL/CML/CLL)2 trialsBreast Cancer1 trialOvarian / Gynecologic Cancer1 trialLymphoma1 trialLeukemia, Plasma Cell1 trial

Research focus

OpenAlex concept fingerprint
Multiple MyelomaLeukemia (AML/ALL/CML/CLL)Breast CancerLymphomaOvarian / Gynecologic Cancer

Drugs & molecules

across trials, industry payments and publications
Sarclisageneric · IsatuximabClinical trialsIndustry payments23Publications2Darzalexgeneric · DaratumumabClinical trialsIndustry payments2Publications5Ninlarogeneric · IxazomibClinical trialsIndustry payments2Publications1

Works with

trial sponsors and companies reporting payments
Genzyme CorporationClinical trialsIndustry payments19Takeda Pharmaceuticals U.S.A., Inc.Clinical trialsIndustry payments13Pfizer Inc.Clinical trialsIndustry payments8

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,164publications

Distinct works indexed by OpenAlex, matched via ORCID; 43 in PubMed.

54,018citations

Total citations across indexed works.

102h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
10clinical trials

Investigator role on registered studies.

View trials
20companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
6NIH grants · 2008–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

20 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    61.7%
    Thalidomide Analog61.7%
    Lenalidomide48%Revlimid38%Pomalyst14%
    Part D<11 patients
  • Anti-infectives

    17.6%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor17.6%
    Valacyclovir100%
    Part D29 patients
  • Sensory organs

    10.2%
    Corticosteroid10.2%
    Dexamethasone100%
    Part D14 patients
2 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)98.2% facility · 1.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

6 NIH research awards on record, funded 20082026 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/cv/robert-orlowski-md-phd

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/robert-orlowski-5b548915

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • X / Twitter

    x.com/Myeloma_Doc

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com

Mentions by others

where others cite or feature them
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com
  • X / Twitter

    X (Twitter) account apparently belonging to Robert Z. Orlowski: @Myeloma_Doc

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    American Board of Internal Medicine - Medical Oncology

    2016
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • M.D.

    Yale University School of Medicine

    1991
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Ph.D.

    Molecular Biophysics & Biochemistry, Yale University

    1990
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • B.A.

    Chemistry, Columbia College, Columbia University

    1983
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org

Editorial & leadership roles

journal and society appointments
  • Editorial Board

    Blood Cancer Discovery

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Editorial Board

    Clinical Cancer Research

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Chair

    SWOG Myeloma Committee

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
1 more role behind the reveal.Reveal →

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • Clinical Medicine
    202120222023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com

Awards & honors

honors on the public record
3 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Professor (Joint Appointment)

    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.